CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 45 enrolled
Drug / intervention
Lubiprostone +1 moredrug
Likely dose
Lubiprostone 24 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00746395
NCT00746395Phase 4Completed
CompareCT.gov

Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy

University of South Alabama·interventional·Posted Sep 4, 2008·Updated Oct 8, 2020

In Brief

A Phase 4 clinical trial evaluating Lubiprostone and Placebo for Inflammatory Bowel Disease. Completed, enrolled 45 participants across 1 site.

Detailed Summary

This investigation is designed to compare lubiprostone and placebo for cleansing and propulsion in preparation for capsule endoscopy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammatory Bowel Disease
CountriesUnited States
CollaboratorsTakeda, Sucampo Pharmaceuticals, Inc.

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 4, 2008
Enrollment StartApr 1, 2008
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 17.8 years ago

Interventions

Lubiprostonedrug

24 mcg oral administration

Placebodrug

Oral administration